---
audienceLevel: patient
cancerTypes:
- lung
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- treatment
title: Amivantamab-vmjw - NCI
url: https://www.cancer.gov/about-cancer/treatment/drugs/amivantamab-vmjw
version: v1
---

# Amivantamab-vmjw - NCI

# Amivantamab-vmjw

Placeholder slot

(A-mih-VAN-tuh-mab)

This page contains brief information about amivantamab-vmjw
and a collection of links to more information about the use of
this drug, research results, and ongoing clinical trials.

US Brand Name(s)

Rybrevant

FDA Approved

Yes

[FDA label information for this drug is available at DailyMed.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1466c070-9f97-4fa4-a955-6a6b59981fb8&audience=consumer)

## Use in Cancer

Amivantamab-vmjw
is approved to treat adults with:

- **[non-small cell lung cancer](/Common/PopUps/popDefinition.aspx?id=45323&version=Patient&language=English)** (NSCLC) that has an abnormal *[EGFR](/Common/PopUps/popDefinition.aspx?id=796876&version=Patient&language=English)* gene and has spread. It is used:
- with [lazertinib mesylate hydrate](/Common/PopUps/popDefinition.aspx?id=816562&version=Patient&language=English) as the first treatment
- with [carboplatin](/Common/PopUps/popDefinition.aspx?id=45182&version=Patient&language=English) and [pemetrexed disodium](/Common/PopUps/popDefinition.aspx?id=45456&version=Patient&language=English) or in patients whose cancer got worse during or after treatment with an [EGFR tyrosine kinase inhibitor](/Common/PopUps/popDefinition.aspx?id=491502&version=Patient&language=English)
- with [carboplatin](/Common/PopUps/popDefinition.aspx?id=45182&version=Patient&language=English) and [pemetrexed disodium](/Common/PopUps/popDefinition.aspx?id=45456&version=Patient&language=English) as the first treatment
- alone in patients whose cancer got worse during or after [platinum](/Common/PopUps/popDefinition.aspx?id=45841&version=Patient&language=English)-based chemotherapy

Amivantamab-vmjw
is also being studied in the treatment of other types of
cancer.

## More About Amivantamab-vmjw

[Definition from the NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/777269) - Detailed scientific definition and other names for this drug.

MedlinePlus Information on [Amivantamab-vmjw](https://medlineplus.gov/druginfo/meds/a621034.html) - A lay language summary of important information about this drug that may include the following:

- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

## Research Results and Related Resources

[Targeted Therapy to Treat Cancer](https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies)

[Monoclonal Antibodies](https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/monoclonal-antibodies)

## Clinical Trials Accepting Patients

[Find Clinical Trials for Amivantamab-vmjw](https://www.cancer.gov/research/participate/clinical-trials/intervention/C124993) - Check for trials from NCI's list of cancer clinical trials now accepting patients.
